Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kshirsagar, Sanjay
- Development of a Validated RP-HPLC Method for Estimation of Ethionamide in Spiked Human Plasma with UV Detection
Abstract Views :146 |
PDF Views:1
Authors
Affiliations
1 Department of Pharmaceutical Analysis, MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik – 422 003, IN
1 Department of Pharmaceutical Analysis, MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik – 422 003, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 6, No 4 (2016), Pagination: 230-234Abstract
A simple, rapid and economic RP-HPLC method was developed and validated for estimation of Ethionamide in spiked human plasma. The drug along with Guaifenesin (used as internal standard) was extracted from plasma by liquid-liquid extraction (LLE) procedure using ethyl acetate as organic solvent. The drug was well resolved from the plasma interference and internal standard in a reversed phase mode on C 18 (250 × 4.6 mm, 5 μ) column with methanol: water (40: 60 %, v/v) as mobile phase, at a flow rate of 1 mL/min. The detection was performed at 275 nm. The developed method was validated as per the US-FDA guidelines, where the weighted linear regression was used in calibration experiments to obtain the homoscedasticity. In accuracy and precision studies, intra-day and inter-day, % relative error was found between ± 15 and % RSD was less than 15 %. Stability experiments indicated that the drug remained stable after three freeze-thaw cycles.Keywords
Ethionamide, Bioanalytical, Liquid-Liquid Extraction, Weighted Regression, RP-HPLC.- Insulin Therapies:Current and Future Trends
Abstract Views :419 |
PDF Views:0
Authors
Affiliations
1 MET’S Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik-422003, Savitribai Phule Pune University, IN
1 MET’S Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik-422003, Savitribai Phule Pune University, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 7, No 4 (2017), Pagination: 189-196Abstract
Many patients with advanced type 2 diabetes mellitus (T2DM) and all patients with T1DM require insulin to keep blood glucose levels in the target range. The most common route of insulin administration is subcutaneous insulin injections. There are many ways to deliver insulin subcutaneously such as vials and syringes, insulin pens, and insulin pumps. Though subcutaneous insulin delivery is the standard route of insulin administration, it is associated with injection pain, needle phobia, lipodystrophy, noncompliance and peripheral hyperinsulinemia. Therefore, the need exists for delivering insulin in a minimally invasive or noninvasive and in most physiological way. Inhaled insulin was the first approved noninvasive and alternative way to deliver insulin, but it has been withdrawn from the market. Technologies are being explored to make the noninvasive delivery of insulin possible. Some of the routes of insulin administration that are under investigation are oral, buccal, nasal, peritoneal and transdermal. This review article focuses on the various insulin delivery techniques. This article has focused on different possible routes of insulin administration with its advantages and limitation and possible scope for the new drug development.Keywords
Diabetes Mellitus, Inhaled Insulin, Insulin Delivery, Oral Insulin, Technology, Closed-Loop System, Artificial Pancreas.References
- Garg, S. K., et al. (2013). Use of non-insulin therapies for type 1 diabetes, Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
- Group, U. P. D. S. (1995). "UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease." Diabetes 44(11): 1249-1258.
- Yaturu, S. (2013). "Insulin therapies: current and future trends at dawn." World J Diabetes 4(1): 1-7.
- Rima B. Shah1, M. P., David M. Maahs, Viral N. Shah (2016). "Insulin delivery methods: Past, present and future " International Journal of Pharmaceutical Investigation 6(1).
- Fry, A. (2012). "Insulin Delivery Device Technology 2012: where are we after 90 years?" Journal of Diabetes Science and Technology 6(4): 947-953.
- Penfornis, A., et al. (2011). "Evolution of devices in diabetes management." Diabetes Technology & Therapeutics13(S1): S-93-S-102.
- Shah, R. B., et al. (2016). "Insulin delivery methods: Past, present and future." International Journal of Pharmaceutical Investigation 6(1): 1.
- Cohen, O., et al. (2009). "Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry." Journal of Diabetes Science and Technology 3(4): 804-811.
- Burdick, P., et al. (2009). "Use of a subcutaneous inj ction port to improve glycemic control in children with type 1 diabetes." Pediatric Diabetes10(2): 116-119.
- Shah, V. N., et al. (2014). Closed-loop system in the management of diabetes: past, present, and future, Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
- A Review on:Quality by Design (QbD)
Abstract Views :463 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik , ,423301, Savitribai Phule Pune University, Maharashtra, IN
2 Department of Pharmaceutical Chemistry, MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik 423301, Savitribai Phule Pune University, Maharashtra, IN
3 MET’s Institute of Pharmacy, Adgaon, Nashik, 423301, Savitribai Phule Pune University, Maharashtra, IN
1 Department of Pharmaceutics, MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik , ,423301, Savitribai Phule Pune University, Maharashtra, IN
2 Department of Pharmaceutical Chemistry, MET’s Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik 423301, Savitribai Phule Pune University, Maharashtra, IN
3 MET’s Institute of Pharmacy, Adgaon, Nashik, 423301, Savitribai Phule Pune University, Maharashtra, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 7, No 4 (2017), Pagination: 197-204Abstract
Quality by Design is the modern approach for quality of pharmaceuticals. Recent pharmaceutical regulatory documents have stressed the critical importance of applying quality by design (QbD) principles for in-depth process understanding to ensure that product quality is built in by design. The purpose of this paper is to discuss the pharmaceutical Quality by Design and describe how it can be used to ensure pharmaceutical quality. Quality cannot be tested into products but quality should be built in by design. Under this concept of QbD throughout designing and development of a product, it is essential to define desire product performance profile [Target product profile (TPP), Target product Quality profile (TPQP) and identify Critical quality attributed (CQA).On the basis of this we can design the product formulation and the process to meet the product attributes. These leads to recognize the impact of raw material Critical material attributes (CMA), Critical process parameter (CPP), on the CQA’s and identification and source of variability. QbD is necessary in regulatory requirement, and to implement new concepts such as design space, ICH guidelines i.e. Q8 pharmaceutical development, Q9 quality risk management, and FDAs process analytical technology (PAT)Keywords
Quality by Design (QbD), Target Product Profile (TPP), Target Product Quality Profile (TPQP), Critical Quality Attributes (CQA), Process Analytical Technology (PAT).References
- Sangshetti JN, Zaheer Z, Mahaparale PR and Chitlange SS. Quality by design (QbD) in pharmaceuticals. Unique Publication, Aurangabad. 1st edition; 2015: 20
- Gawade A, Chemate S and Kuchekar A. Pharmaceutical Quality by Design: A New Approach in Product Development. Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences. 2013; 2:5-11.
- Juran JM. On quality by design the new steps for planning quality into goods and services New York free press. 1992; 1-2.
- Food and Drug Administration. Final Report on Pharmaceutical cGMPs for the 21st Century - A Risk Based Approach. [Online] Available at: http://www.fda.gov/ cder/ gmp/ gmp 2004/ GMP_ final report 2004.htm. Accessed 10 March 2016.
- Jain S. Quality by Design (QbD): A Comprensive understanding of implementation and challenges in pharmaceutical development. Int J of Pharm Pharma Sci. 2014; 6:29-35.
- US Food and Drug Administration. Guidance for industry: Q8 (R2) pharmaceutical development. US Department of Health and Human Service, FDA, Rockville, MD; 2009.
- Looby M, Ibarra N, Pierce JJ, Buckley K, O'Donovan E, Heenan M, et al. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein. Biotechnology Progress. 2011; 27(6): 1718-29.
- Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality by Design: A complete review. Int. J. Pharm. Sci, Rev Res. 2012; 2: 20-8.
- Roy S, Quality by design: A holistic concept of building quality in pharmaceuticals. International Journal of Pharmaceutical and Biomedical Research .2012; 3 (2): 100-108.
- Chang RK, Raw A, Lionberger R, Yu L. Generic development of topical dermatologic products, part II: quality by design for topical semisolid products. AAPS J. 2013; 15(3): 674.
- McConnell J, McGarvey B, Nunnally B. Quality risk management and variability reduction. Journal of Validation Technology. 2011:12-6.
- Mollah H, Baseman H, Long M. Risk Management Applications in Pharmaceutical and Biopharmaceutical Manufacturing: Wiley; 2013.
- White E. Risk Management for Aseptic Processing. Journal of Validation Technology. 2009; 15(2): 25-33.
- Gad SC. Handbook of Pharmaceutical Biotechnology. Gad SC, editor: Wiley; 2007.
- Keizer JA, Vos J-P, Halman JIM. Risks in new product development: devising a reference tool. R&D Management. 2005; 35(3):297-309.
- Ranga S, Jaimini M, Sharma SK, Chauhan BS, Kumar A. A review on design of experiment. International Journal of Research and Reviews in Pharmacy and Applied science. 2013; 3(6): 867-82.
- Monica RP, Rao P. Preparation and evaluation of immediate release tablets of meroclopramide HCL using Simplex Centruoid Mixture Design. International Journals of Pharma Tech Research. 2010; 2:1105.
- Q8 Pharmaceutical Development – FDA guidance.
- Kovalycsik M. Design Space and PAT - Q8 ICH Draft Guidance on Pharmaceutical Development. AVP, Wyeth Research Vaccines R&D, Quality Operations.
- Khare R. Three Romeos And A Juliet An Early Brush With Design Of Experiments. www.isixsigma.com. Accessed 10 March 2016.
- Burnham R. How to Select Design of Experiments Software. www.sixsigma.com. Accessed 10 March 2016.
- Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, et al. Understanding pharmaceutical Quality by design. AAPS Journal. 2014; 16:771-83.
- ICH Quality Implementation working group. Point to consider, ICH endorsed guide for ICH Q8/Q9/Q10 implementation. 2011
- Altan S, Bergum J, Pfahler L, Senderak E, Sethuraman S, Vukovinsky KE. Statistical Considerations in Design Space Development Part I of III. Pharmaceutical Technology. 2010; 34(7): 66-70
- Jadhav J, Girawale N, Chaudhari R, Quality by Design (QBD) Approach used in Development of Pharmaceuticals International Journals of Pure and Applied Bioscience. 2014; 2 (5): 21
- Development and Validation of Stability Indicating RP-HPLC Method for Piracetam
Abstract Views :390 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Chemistry, MET's Institute of Pharmacy, Bhujbal Knowledge City, Adgaon Nashik, Maharashtra, IN
2 Savitribai Phule Pune University, Pune, Maharshtra state, IN
1 Department of Pharmaceutical Chemistry, MET's Institute of Pharmacy, Bhujbal Knowledge City, Adgaon Nashik, Maharashtra, IN
2 Savitribai Phule Pune University, Pune, Maharshtra state, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 7, No 4 (2017), Pagination: 215-221Abstract
A simple, rapid and validated HPLC method was developed for determination of Piracetam in film coated tablets. A Grace C18 (250mm x 4.6ID, Particle size: 5 micron) RP-18 column with a mobile phase consisting of Methanol: Water (20:80v/v) was used. Quantitative evaluation was performed at 205 nm. The HPLC method is selective, precise and accurate and can be used for routine analysis of preparations in pharmaceutical industry quality control laboratories.Keywords
RP-HPLC, Force Degradation Study, Piracetam.References
- V. Masarskal Analytical Method Development and Validation For Piracetam In Pharmaceutical Formulation Pharmacia, vol. 60, No. 4/2013
- Sushil D. Patil, Sunil V. Amurutkar and C. D. Upasani Development and Validation of Stability Indicating RP-HPLC Method for Empagliflozin Asian J. Pharm. Ana. 2016,Vol. 6; Issue 4
- Manutosh Acharya1, A.K Jain, et al RP-HPLC Method Development And Validation For Simultaneous Determination of Citicoline And Piracetam In Pharmaceutical Dosage Form Indo American Journal of Pharmaceutical Research, 2015, Vol 5, Issue 08, 3639-3647.
- Bhowmick Anindita A., Khandelwal, et al Analytical Method Development and Validation for Piracetam as Bulk and in Pharmaceutical Formulation International Journal of PharmTech Research.2010,Vol.2, No.1, pp 201-204,
- International Conference on harmonization. Guideline on Validation of Analytical Procedure. Text and Methodology. ICH – Q2 (R1); 2005.
- Bakshi, Monika, and Saranjit Singh. "Development of Validated Stability-Indicating Assay Methods—Critical Review." Journal of Pharmaceutical and Biomedical Analysis 2002, 28.61011-40.
- Snyder L.R., Kirkland J. and Glajch J. (1997) Practical HPLC Method Development, 2nd ed. New York: John Wiley and Sons.
- Government of India, Indian Pharmacopoeia Commission Ministry of Health and Welfare (2007) Indian Pharmacopoeia, Ghaziabad India
- Hong, Donald H., and Mumtaz Shah. "Development and Validation of HPLC Stability Indicating Assays." Drug Stability Principles and Practices. Ed. Christensen, Jens Thur. 3ed. New York: M. Dekker, 2002. 329-84.
- Q1BICH. "Photostability Testing of New Drug Substances and Products Q1B."International Conference on Harmonization. Geneva: ICH, 1996.
- Q2 (R1) ICH. "Validation of Analytical Procedures: Text and Methodology Q2 (R1)."International Conference on Harmonization. Geneva: ICH, 2005.
- Predicting the Anti-Inflammatory Activity of Novel 5-Phenylsulfamoyl-2-(2-Nitroxy) (Acetoxy) Benzoic Acid Derivatives using 2D and 3D-QSAR (kNN-MFA) Analysis
Abstract Views :370 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Chemistry, Bhujbal Knowledge City, MET’S IOP, Adgaon, Nashik-422003, IN
1 Department of Pharmaceutical Chemistry, Bhujbal Knowledge City, MET’S IOP, Adgaon, Nashik-422003, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 7, No 4 (2017), Pagination: 227-234Abstract
The quantitative structure–activity relationship (QSAR) analyses were carried out for a series of new side chain modified 5-phenylsulfamoyl-2-(2-nitroxy) (acetoxy) benzoic acid derivatives to find out the structural requirements of their anti-inflammatory activities. The statistically significant best 2D QSAR models for anti-inflammatory activity having correlation coefficient (r2) = 0.897 and cross validated squared correlation coefficient (q2) = 0.701 with external predictive ability (pred_r2) = 0.390 were developed by multiple linear regression coupled with genetic algorithm (GA–MLR) and stepwise (SW–MLR) forward algorithm, respectively. The results of the present study may be useful on the designing of more potent analogues as antimalarial agents.Keywords
QSAR, 5-Phenylsulfamoyl-2-(2-Nitroxy) (Acetoxy) Benzoic Acid, Anti-Inflammatory, MLR, Genetic Algorithm.References
- H. Abadi, et al. (2005), Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents, Bioorganic and Medicinal Chemistry , 13, pp. 5759–5765.
- U. K. Bandarage, et al. (2000) Nitrosothiol esters of diclofenac synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs, Journal of Medicinal Chemistry, 43, pp. 4005-16.
- S. V. Bhandari, et al. (2009) Design, synthesis and pharmacological screening of novel nitric oxide donors containing 1,5-diarylpyrazolin-3-one as nontoxic NSAIDs, European Journal of Medicinal Chemistry, 44, pp.4622–4636
- Ajmani, S., Jadhav, K., and Kulkarni, S. (2006), Three-dimensional QSAR using the k-nearest neighbor method and its interpretation. Journal of chemical information and modeling, 46, pp. 24-31.
- BOLTON, S. and BON, C. (2004), Pharmaceutical Statistics- Practical and Clinical Application 4th Ed. New York, USA: Marcel Dekker Inc.
- C. Cena, et al. (2003) Anti-inflammatory, Gastro sparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin, Journal of Medicinal Chemistry, 46, pp. 747- 54.
- M. A. Chowdhury, et al. (2010), Celecoxib analogs possessing a N-(4-nitrooxybutyl) piperidin-4-yl or N-(4- nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: Synthesis, biological evaluation and nitric oxide release studies, Bioorganic and Medicinal Chemistry Letters , 20, pp.1324–1329
- M. A. Chowdhury, et al. (2008), Synthesis of new 4-[2-(4-methyl (amino) sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1, 2, 3, 6-tetrahydropyridines: A search for novel nitric oxide donor anti-inflammatory agents, Bioorganic and Medicinal Chemistry, 16, pp.8882–88
- B. C. Daniel, et al. (2008), Non-steroidal Anti-inflammatory Agents – Benefits and New Developments for Cancer Pain, Supportive Oncology, pp. 18-22.
- J. E Downing, et a.l (2005) Gastric and thymic assay of acute oral treatment of rats with nitric oxide esters of ibuprofen or indomethacin, Biochem. Biophys. Res. Commun.
- O. O. Fadeyi, et al (2004) Antipyretic, analgesic, anti-inflammatory and cytotoxic effects of four derivatives of salicylic acid and anthranilic acid in mice and rats, African Journal of Biotechnology, 3(8), pp. 426-431
- S. Fiorucci, J. L. Wallace, R. N. Dubois, et al.(2000) New anti-inflammatory agents: NO-NSAIDS and COX-2 inhibitors. International conference on “Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications”, June (4-8), pp. 2.
- S. Fioruccia, et al. (2007), NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: What lies beyond the horizon, Digestive and Liver Disease, 39, pp. 1043–1051.